COO is the ticker symbol for COOPER COMPANIES, INC., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks COO with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is COO a good stock to buy?

13F Pro's AI ranking engine scores COO at 65.7/100, ranked #459 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for COO is available at https://13fpro.ai/company/COO. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source COO data?

All COOPER COMPANIES, INC. fundamentals and ownership data come directly from SEC EDGAR. COOPER COMPANIES, INC. files with the SEC under CIK 711404. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

COOPER COMPANIES, INC. COO

NasdaqLarge CapHealthcare

13F Pro quality score

Rank #459 of 2,925TOP 25%

Why it scores 66 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$1.07B

Quarter to Jul 31

Net income

$432.80M

Quarter to Jul 31

Free cash flow

$273.00M

Quarter to Jul 31

Operating margin

20.8%

Quarter to Jul 31

Top Institutional Holders

as of Q2 2026

$15.00B total

BlackRock, Inc.

$1.08B-9.6%

VANGUARD CAPITAL MANAGEMENT LLC

$914.93M+0.3%

STATE STREET CORP

$637.69M+1.4%

VANGUARD PORTFOLIO MANAGEMENT LLC

$621.70M-0.6%

T. Rowe Price Investment Management, Inc.

$532.77M-18.0%

BROWNING WEST LP

$515.98M+3.1%

PRICE T ROWE ASSOCIATES INC /MD/

$400.12M+3.4%

KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC

$389.41M-17.9%

GEODE CAPITAL MANAGEMENT, LLC

$382.87M+0.9%

FRANKLIN RESOURCES INC

$365.50M+4.7%

GENERATION INVESTMENT MANAGEMENT LLP

$356.30M+8.0%

Jupiter Topco LLC

$305.07M--

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$287.15M+88.3%

AQR CAPITAL MANAGEMENT LLC

$285.69M+7.9%

Longview Partners (Guernsey) LTD

$282.54M+3.1%

UBS Group AG

$281.96M+14.5%

CITADEL ADVISORS LLC

$277.69M+1911.4%

Invesco Ltd.

$264.25M+0.8%

JANA Partners Management, LP

$256.90M+0.5%

WELLINGTON MANAGEMENT GROUP LLP

$248.76M+3.1%

DIMENSIONAL FUND ADVISORS LP

$239.62M+61.5%

LONDON CO OF VIRGINIA

$207.82M+29.5%

DIAMOND HILL CAPITAL MANAGEMENT INC

$195.85M-19.6%

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

$187.84M-10.5%

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME

$182.79M+0.7%

See all 681 institutional holders →

What's Driving COO's Business? Latest 10-Q Breakdown

20/20 datapoints verified

AI-extracted from the 10-Q filed 2026-09-09 — Q3 FY2026 (quarter ended July 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

CooperVision operating income grew 1% to $205.5M despite flat sales, while CooperSurgical swung to $41.1M profit; company accrued $272M litigation expense for LifeGlobal embryo culture media recall.

Biggest Revenue Drivers

CooperVision$717.0M0% YoY

Toric and multifocal growth from MyDay offset by lower legacy hydrogel sales; sphere other declined due to legacy products.

CooperSurgical$349.2M+2% YoY

Office and surgical increased from surgical products; fertility grew from genetic testing revenue.

Biggest Revenue Drivers

Total revenue: $1,066.2M+0.6% YoY

CooperVision$717.0M0% YoY

Toric and multifocal growth from MyDay offset by lower legacy hydrogel sales; sphere other declined due to legacy products.

CooperSurgical$349.2M+2% YoY

Office and surgical increased from surgical products; fertility grew from genetic testing revenue.

Largest Expense Items

Cost of sales$354.3M-3.8% YoY

Inventory write-offs from product line exit in fiscal 2025 benefited prior-year gross margin.

Selling, general and administrative$401.3M-4.8% YoY

Headcount reductions across CooperVision and CooperSurgical offset strategic review costs.

Research and development$41.6M-6.7% YoY

Lower R&D project spend at CooperVision partially offset by pharmacovigilance fees.

Margins: Consolidated gross margin improved to 67% from 65% YoY, primarily from inventory write-offs benefiting the prior-year comparison. Operating margin expanded to 21% from 17% despite the LifeGlobal litigation accrual, driven by CooperVision's operational efficiency gains.

Watch Items from the Filing

CooperSurgical recorded $272.0M litigation expense (net of $53.8M insurance recovery) for LifeGlobal embryo culture media recall; 140+ lawsuits filed with 1,500+ claimants; $306.8M settled in August 2026.
CooperVision sales flat YoY in Q3; sphere category declined 2% and Americas down 2%, partly from U.S. channel inventory reductions; Asia Pacific down 10% due to Japan and China softness.
U.K. First-tier Tribunal issued March 2, 2026 decision largely supporting HMRC in Sauflon acquisition payroll tax dispute; company appealing with potential exposure of £0–£71.7M plus interest.
Discrete tax benefit of $307.2M recognized in Q3 from release of uncertain tax position after favorable June 2026 tax authority examination on IP transfer valuation.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q3 2026

EDGAR

Net Income

Q3 2026

EDGAR

EPS (Diluted)

Q3 2026

EDGAR

Operating Margin

Q3 2026

EDGAR

ROIC

Q3 2026

EDGAR

Free Cash Flow

Q3 2026

EDGAR

Debt/Equity

Q3 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/COO

Earnings Per Share

13fpro.ai/company/COO

Loading ratio trend…

COOPER COMPANIES, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$4.1B	$374.9M	16.7%
FY 2024	10-K	$3.9B	$392.3M	18.1%
FY 2023	10-K	$3.6B	$294.2M	14.8%
FY 2022	10-K	$3.3B	$385.8M	15.3%
FY 2021	10-K	$2.9B	$2.9B	17.3%
FY 2020	10-K	$2.4B	$238.4M	12.8%

About COOPER COMPANIES, INC. (COO): stock profile, AI score and financials

COOPER COMPANIES, INC. (COO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores COO at 65.7/100 on a composite quality score built from its SEC filings, placing it at rank #459 of 2,925 stocks — the top 25% of the AI-ranked universe. COO scores in the top quartile across earnings quality (81.0), revenue scale (75.5), profitability (75.0). Shareholder dilution risk is elevated at 41.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), COOPER COMPANIES, INC. reports quarterly revenue of $1.1B, net income of $432.8M, an operating margin of 20.8%. Top institutional holders of COO by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. COO trades on the Nasdaq exchange and files with the SEC under CIK 711404. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for COOPER COMPANIES, INC. directly from SEC EDGAR.

Financials through the period ended Jul 31, 2026SEC EDGAR: CIK 711404 →

COOPER COMPANIES, INC. COO

Top Institutional Holders

What's Driving COO's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

COO key financials by period

COO insiders

Congress trading in COO

About COOPER COMPANIES, INC. (COO): stock profile, AI score and financials

COOPER COMPANIES, INC. COO

Top Institutional Holders

What's Driving COO's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

COO key financials by period

Companies similar to COO

COO insiders

Congress trading in COO

About COOPER COMPANIES, INC. (COO): stock profile, AI score and financials